What did @bbcnews actually say?
The video claims that "genes could be part of the reason" some people lose more weight on GLP-1 drugs than others. It references a study of 15,000 people on GLP-1 medications where results varied widely, some losing 30% of body weight, others losing almost nothing. One gene variant was tied to an extra 1.6 pounds of loss on average, potentially doubling with two copies. A separate variant may explain GI side effects like nausea and vomiting. The report also states that younger people and women tend to lose more weight on these drugs.
The framing is notably cautious. Genes "play a part" is accurate hedging, and BBC News does not claim this is predictive or actionable yet. That restraint deserves credit.
Does the science back this up?
Mostly, yes. The study being referenced appears to be the large-scale pharmacogenomic analysis published in 2024, consistent with work from groups including Lotta et al. and analyses from the UK Biobank cohort. Research into GLP-1 receptor gene variants (GLP1R) and related appetite-regulating pathways has shown real, if modest, associations with differential drug response. The 1.6-pound figure is small enough to be plausible rather than inflated.
The sex and age findings also have backing. A 2022 analysis in Diabetes, Obesity and Metabolism (Rubino et al.) found women on semaglutide lost modestly more weight than men in some trial arms, and younger baseline age correlated with greater response in several post-hoc analyses of STEP trial data. These are real signals, not invented ones, though effect sizes vary by study.
What the video does not say, but should, is that the absolute genetic effect described is small. An extra 1.6 pounds is a statistical signal, not a clinical game-changer by itself.
What did they get wrong or right?
The drug names are mangled. "Wargovian" is clearly a garbled version of Wegovy, and "Monjaro" is a mispronunciation of Mounjaro. These are brand-name medications, semaglutide and tirzepatide respectively, and getting them wrong in a health video watched by 186,000 people is a real problem. Someone searching for information after watching this may not find what they need.
The claim that these drugs "fight hunger" is a simplification but not wrong. GLP-1 receptor agonists slow gastric emptying, reduce appetite signaling in the hypothalamus, and affect dopaminergic reward pathways. Saying they make you "eat less" captures the outcome but skips the mechanism in a way that can make the drugs sound more straightforward than they are.
The genetic side-effect claim, specifically that a gene variant may explain nausea and vomiting, is plausible and lines up with early pharmacogenomic research, but the video presents it as more established than the current evidence supports. This is an area of active investigation, not settled science.
What should you actually know?
Pharmacogenomics for GLP-1 drugs is a real and growing field, but it is not clinically deployable yet. No genetic test currently exists that a prescriber can order to predict your individual response to semaglutide or tirzepatide with meaningful accuracy. The study signals are early-stage and the effect sizes, like that 1.6-pound figure, are modest compared to the overall variance in treatment outcomes.
The bigger drivers of response are likely behavioral, metabolic, and adherence-related rather than purely genetic. Baseline BMI, insulin resistance status, sleep quality, and how consistently someone takes their medication account for a large share of the variation clinicians actually see.
If you are on a GLP-1 medication and not seeing results, the answer is not to blame your genes. It is worth talking to a prescriber about dose titration, injection technique, dietary context, and whether the medication class is the right fit for your specific metabolic profile.